AstraZeneca’s Alexion posts 52-week PREVAIL data backing once-weekly self-injected C5 inhibitor gefurulimab in gMG

By Public Technologies
  • AstraZeneca flagged new long-term trial results for gefurulimab in generalized myasthenia gravis, scheduled for presentation in late September 2026.
  • Data from the PREVAIL Phase 3 open-label extension indicated sustained symptom control through 52 weeks in treated adults.
  • Patients switching from placebo showed rapid improvement soon after starting therapy, with benefits maintained to one year.
  • Safety profile remained consistent, with no meningococcal infections reported, supporting positioning as a self-administered weekly injection.
  • Separate analyses due at the same meetings pointed to fewer hospitalizations and less rescue therapy use versus placebo earlier in the study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.